Fig. 1

Characteristics of twenty CD22 CAR T-cell products manufactured at CCE of the NIH Clinical Center. a Viable total nucleated cells (TNC) count at the start of the CD22 manufacturing process (470 × 10⁶) doubled over the time of the 9-day culturing process to 1.1 × 10⁹ of viable TNC at the harvest. b Fold expansion rate reached its maximum on D7 of the manufacturing process (8.5) with a drop at the harvest (2.9). c CD3 percentage increased over the culturing process from 48% at apheresis bag to 99.7% of CD3⁺ at the harvest. d Transduction efficiency measured via flow cytometry reached 43% of protein L⁺ cells at the culture harvest. e CD4/CD8 ratio at the harvest